Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.
Technical Indicators:
- 100% Barchart technical buy signals
- 61.60+ Weighted Alpha
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 8 new highs and up 14.55% in the last month
- Relative Strength Index 63.22%
- Barchart computes a technical support level at 33.22
- Recently traded at 36.69 with a 50 day moving average of 32.51
- Market Cap $1.52 billion
- The Revenue and earnings estimated are not reliable because they are all over the place
- Wall Street analysts issued 6 strong buy, 2 buy and 6 hold recommendations on the stock
No comments:
Post a Comment